Farmaceutica REMEDIA S.A.

BVB:RMAH Stock Report

Market Cap: RON 58.5m

Farmaceutica REMEDIA Past Earnings Performance

Past criteria checks 1/6

Farmaceutica REMEDIA's earnings have been declining at an average annual rate of -21.6%, while the Consumer Retailing industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 9.1% per year. Farmaceutica REMEDIA's return on equity is 3.9%, and it has net margins of 0.4%.

Key information

-21.6%

Earnings growth rate

-19.9%

EPS growth rate

Consumer Retailing Industry Growth12.4%
Revenue growth rate9.1%
Return on equity3.9%
Net Margin0.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Returns At Farmaceutica REMEDIA (BVB:RMAH) Are On The Way Up

Mar 04
Returns At Farmaceutica REMEDIA (BVB:RMAH) Are On The Way Up

Farmaceutica REMEDIA's (BVB:RMAH) Returns On Capital Are Heading Higher

Mar 07
Farmaceutica REMEDIA's (BVB:RMAH) Returns On Capital Are Heading Higher

Returns Are Gaining Momentum At Farmaceutica REMEDIA (BVB:RMAH)

Aug 18
Returns Are Gaining Momentum At Farmaceutica REMEDIA (BVB:RMAH)

We Like These Underlying Return On Capital Trends At Farmaceutica REMEDIA (BVB:RMAH)

Mar 23
We Like These Underlying Return On Capital Trends At Farmaceutica REMEDIA (BVB:RMAH)

Does Farmaceutica REMEDIA (BVB:RMAH) Deserve A Spot On Your Watchlist?

Feb 16
Does Farmaceutica REMEDIA (BVB:RMAH) Deserve A Spot On Your Watchlist?

Is There More To The Story Than Farmaceutica REMEDIA's (BVB:RMAH) Earnings Growth?

Jan 15
Is There More To The Story Than Farmaceutica REMEDIA's (BVB:RMAH) Earnings Growth?

Is Farmaceutica REMEDIA S.A.'s (BVB:RMAH) Recent Performance Tethered To Its Attractive Financial Prospects?

Dec 16
Is Farmaceutica REMEDIA S.A.'s (BVB:RMAH) Recent Performance Tethered To Its Attractive Financial Prospects?

Should You Invest In Farmaceutica REMEDIA (BVB:RMAH)?

Nov 18
Should You Invest In Farmaceutica REMEDIA (BVB:RMAH)?

Revenue & Expenses Breakdown

How Farmaceutica REMEDIA makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BVB:RMAH Revenue, expenses and earnings (RON Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 247143230
30 Jun 246643220
31 Mar 246307210
31 Dec 235937210
30 Sep 235677230
30 Jun 235596230
31 Mar 235496230
31 Dec 225366220
30 Sep 225236220
30 Jun 225187210
31 Mar 224907190
31 Dec 214777190
30 Sep 214537190
30 Jun 2143943200
31 Mar 2143341230
31 Dec 2044138280
30 Sep 2045237320
30 Jun 20457-1350
31 Mar 204591360
31 Dec 194462350
30 Sep 194572340
30 Jun 194643340
31 Mar 194702330
31 Dec 184643320
30 Sep 184393300
30 Jun 184045290
31 Mar 183765270
31 Dec 173514260
30 Sep 173264240
30 Jun 173062230
31 Mar 172802220
31 Dec 162551210
30 Sep 162381200
30 Jun 162331210
31 Mar 162280190
31 Dec 152401190
30 Sep 152471200
30 Jun 152422200
31 Mar 152473200
31 Dec 142483200
30 Sep 142384180
30 Jun 142373160
31 Mar 142413180
31 Dec 132383180

Quality Earnings: RMAH has high quality earnings.

Growing Profit Margin: RMAH's current net profit margins (0.4%) are lower than last year (1.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: RMAH's earnings have declined by 21.6% per year over the past 5 years.

Accelerating Growth: RMAH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: RMAH had negative earnings growth (-62.1%) over the past year, making it difficult to compare to the Consumer Retailing industry average (-8.4%).

Return on Equity

High ROE: RMAH's Return on Equity (3.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 16:36
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Farmaceutica REMEDIA S.A. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Virgil LivanovFairwind Consulting